Clinical Trials Browser

Phase 1/2 × Leukemia, Biphenotypic, Acute × quizartinib × Clear all

NCT04047641 2025-12-17

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute